Radiation and immunotherapy combo targets untreatable liver tumors

NCT ID NCT07482059

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of internal radiation (Y90-SIRT) with three drugs (nivolumab, ipilimumab, and lenvatinib) in 33 people with liver cancer that cannot be surgically removed. The goal is to see if this powerful mix is safe and can shrink tumors or extend survival. It is an early-stage trial, so the main focus is on safety and finding the right doses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Yttrium-90 microspheres, nivolumab, ipilimumab, and lenvatinib
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong: This is an early-phase trial with only 33 participants, so results may not apply to everyone. The combination of multiple drugs and radiation may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Study Chair Liu Chang , West China Hospital
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.